Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Girl sues India to get TB drug

by K. V. Venkatasubramanian, special to C&EN
January 16, 2017 | A version of this story appeared in Volume 95, Issue 3

A teenager fighting extremely drug-resistant tuberculosis is asking an Indian court to force the national government to lift its restrictions on bedaquiline. This antibiotic is made by Johnson & Johnson and in 2012 became the first new treatment for TB to be introduced in more than four decades. India has imposed strict controls on bedaquiline because medical experts believe overuse of older antibiotics has resulted in a spate of drug-resistant TB in the country. India says the restricted use of bedaquiline will preserve its effectiveness. It is available only in five of India’s 29 states and is available only as a last resort. It is given to patients on a case-by-case basis if the pharmaceutical company agrees after considering the patient’s situation. The antibiotic, which is the first to inhibit the proton pump of the tuberculosis bacterium’s ATP synthase enzyme, is not manufactured in India. The government has 300 doses of bedaquiline available under a pilot project in five states, but the 18-year-old girl doesn’t qualify for one.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.